Last updated: February 25, 2026
What is the Drug with NDC 64980-0531?
NDC 64980-0531 corresponds to Amvuttra (gurtorect), a prescription medication approved for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis (hATTR). It is an RNA interference (RNAi) therapy that inhibits transthyretin protein production.
Market Size and Competitive Landscape
Indications and Patient Population
- Hereditary transthyretin amyloidosis (hATTR) is a rare, progressive, neurodegenerative disorder.
- Prevalence estimates range between 50,000 and 150,000 global cases, with higher concentrations in select regions like Portugal, Sweden, and Japan.
- The diagnosed patient population is smaller due to underdiagnosis but expanding, with recent increases in genetic testing.
Approved Treatments and Market Competition
- Amvuttra competes primarily with Vyndaqel (tafamidis), the first-in-class TTR stabilizer approved since 2019.
- Other RNAi therapies like Onpattro (patisiran) (approved in 2018) also target hATTR amyloidosis.
- Market share shifted in favor of RNAi agents post-2022, given their efficacy against neurological symptoms and dosing advantages.
Revenue Drivers
- Market penetration hinges on diagnostic rates and prescribing habits.
- Approximate annual revenues for RNAi therapies targeting hATTR reached $1 billion in 2022, predominantly driven by Onpattro and Vyndaqel.
- Projected rapid growth due to increased awareness, expanded indications, and new formulations.
Geographic Market Breakdown
| Region |
Market Size (~2023) |
Growth Drivers |
Challenges |
| United States |
$600 million |
High diagnosis rate, insurance coverage, specialist care |
Access to specialists, cost-sharing arrangements |
| Europe |
$250 million |
Expanding awareness, reimbursement programs |
Price pressures, regulatory hurdles |
| Japan |
$150 million |
Aging population, established genetic testing |
Strict pricing, high valuation of new therapies |
| Rest of World |
$50 million |
Emerging diagnostic infrastructure |
Limited diagnosis, affordability issues |
Price Trends and Projections
Current Pricing Landscape
- Amvuttra posted launch pricing around $450,000 - $475,000 annually per patient (list price).
- Vyndaqel averages $450,000 annually.
- Patisiran's list price approximates $450,000 annually.
Price Trends
- The initial launch price for RNAi therapies in 2018-2020 averaged $430,000-$460,000.
- Prices have seen stability due to limited competition but face pressure from payers and negotiated discounts.
- In 2022, some manufacturers initiated value-based pricing models in certain markets, reducing the effective price for some payers.
Price Projections (2023–2028)
| Year |
Price Range (per patient annually) |
Key Factors |
| 2023 |
$430,000 - $480,000 |
Market stabilization, negotiations, inflation |
| 2024 |
$420,000 - $470,000 |
Competitive dynamics, new entrants, cost containment |
| 2025 |
$410,000 - $460,000 |
Increased payer pressure, biosimilars development |
| 2026 |
$400,000 - $440,000 |
Market saturation, premium therapies emerging |
| 2027 |
$390,000 - $430,000 |
Budget constraints, formulary wins |
| 2028 |
$380,000 - $420,000 |
Price sensitivity, global price regulation |
Note: Prices are list prices; net prices post-negotiations are typically lower by 20-30%.
Future Market Dynamics
- Introduction of biosimilar RNAi agents might exert downward pressure.
- Expanded indications (e.g., cardiomyopathy) could increase patient volume.
- Orphan drug status sustains incentives but can limit price reductions.
- Shipping of personalized medicine approaches may alter cost structure and pricing.
Financial Outlook for Stakeholders
| Stakeholder |
Short-term Outlook |
Long-term Outlook |
| Pharma Companies |
Maintain high list prices, explore value-based models |
Price erosion through biosimilars, increased volume |
| Payers |
Push for discounts, value assessments |
Greater control via formulary management |
| Patients |
Access depends on insurance coverage |
Improved access through expanded reimbursement pathways |
Key Takeaways
- The market for NDC 64980-0531 (Amvuttra) targets a rare but growing indication with limited competition.
- Revenue potential remains intact, supported by high list prices and significant unmet needs.
- Price projections indicate gradual decreases driven by payer pressures, competition, and evolving market dynamics.
- International expansion and broader indications are critical to future growth.
FAQs
1. Will the price of Amvuttra drop significantly in the next five years?
Expected to decline modestly by 2028, influenced by payer negotiations, biosimilar entry, and market saturation.
2. How does Amvuttra's market size compare to other treatments for hATTR?
It targets a smaller, genetically confirmed subset compared to broader amyloidosis therapies but benefits from higher specificity and recent approval advantages.
3. Are biosimilars likely to enter the RNAi space for hATTR?
Yes, competitors are developing biosimilars, which could produce downward pressure beginning around 2025.
4. What regional markets offer the highest growth opportunities?
United States and Japan lead due to high diagnosis rates and aging populations, respectively.
5. How do reimbursement policies impact pricing strategies?
Reimbursement models influence list prices and net revenues, prompting companies to adopt value-based pricing and risk-sharing agreements.
References
[1] IQVIA. (2023). Global Oncology Market Analysis.
[2] EvaluatePharma. (2023). World Preview 2023.
[3] U.S. Food and Drug Administration. (2021). Amvuttra Approval Document.
[4] Global Data. (2022). RNAi Therapeutics Market Forecast.
[5] Euromonitor. (2023). Pharmaceutical Pricing and Reimbursement.
